
Kura Oncology, Inc.: shareholders and insiders
Price
$6.91
November 20, 2026Market cap $610M
What Ploutos Investor adds for Kura Oncology
Part of Ploutos Investor, €9.99 a month
- The full history: 3 fiscal years, from 2023
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
Insiders and their shares
Purchases and sales by officers and directors from Nov 22, 2025 to Nov 19, 2026, from their own Form 4 filings.
Bought on the market
$3.9M
1 person
Sold on the market
$4.0M
7 people
From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan68%
- The rest32%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $3.9M by 1 person·sold $3.7M by 6 people
- 2025: no buys, sold $341.8K by 2 people
- 2026: bought $3.9M by 1 person, sold $3.7M by 6 people
- Nov 19, 2026Brian T. PowlChief Commercial OfficerKind10b5-1
- Nov 17, 2026Mollie LeoniChief Medical OfficerKind10b5-1
- Nov 17, 2026Brian T. PowlChief Commercial OfficerKind10b5-1
- Nov 17, 2026Kathleen FordChief Operating OfficerKind10b5-1
- Nov 16, 2026Thomas James DoyleSVP, Finance & AccountingKind
- Nov 16, 2026Mollie LeoniChief Medical OfficerKind
- Nov 16, 2026Brian T. PowlChief Commercial OfficerKind
- Nov 16, 2026Teresa Brophy BairChief Legal OfficerKind10b5-1
- Nov 16, 2026Kathleen FordChief Operating OfficerKind10b5-1
- Nov 16, 2026Troy Edward WilsonPresident and CEOKind
- Nov 13, 2026Troy Edward WilsonPresident and CEOKind
- Sep 29, 2026Kathleen FordChief Operating OfficerKind10b5-1
- Sep 29, 2026Mollie LeoniChief Medical OfficerKind10b5-1
- Sep 29, 2026Brian T. PowlChief Commercial OfficerKind10b5-1
- Sep 28, 2026Teresa Brophy BairChief Legal OfficerKind10b5-1
- Sep 28, 2026Kathleen FordChief Operating OfficerKind10b5-1
- Sep 28, 2026Mollie LeoniChief Medical OfficerKind
- Sep 28, 2026Thomas James DoyleSVP, Finance & AccountingKind
- Sep 28, 2026Brian T. PowlChief Commercial OfficerKind
- Sep 28, 2026Brian T. PowlChief Commercial OfficerKind10b5-1
- Sep 24, 2026Francis BurrowsChief Scientific OfficerKind
- Sep 24, 2026Francis BurrowsChief Scientific OfficerKind
- Aug 24, 2026Troy Edward WilsonPresident and CEOKind
- Aug 21, 2026Brian T. PowlChief Commercial OfficerKind10b5-1
- Aug 19, 2026Teresa Brophy BairChief Legal OfficerKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 19, 2026 | Brian T. PowlChief Commercial Officer | 10b5-1 | 448 | $7.27 | $3.3K | Form 4 |
| Nov 17, 2026 | Mollie LeoniChief Medical Officer | 10b5-1 | 22.2K | $7.45 | $165.7K | Form 4 |
| Nov 17, 2026 | Brian T. PowlChief Commercial Officer | 10b5-1 | 15.3K | $7.45 | $113.6K | Form 4 |
| Nov 17, 2026 | Kathleen FordChief Operating Officer | 10b5-1 | 3,668 | $7.46 | $27.4K | Form 4 |
| Nov 16, 2026 | Thomas James DoyleSVP, Finance & Accounting | 4,697 | $7.44 | $34.9K | Form 4 | |
| Nov 16, 2026 | Mollie LeoniChief Medical Officer | 19.0K | $7.44 | $141.4K | Form 4 | |
| Nov 16, 2026 | Brian T. PowlChief Commercial Officer | 9,196 | $7.44 | $68.4K | Form 4 | |
| Nov 16, 2026 | Teresa Brophy BairChief Legal Officer | 10b5-1 | 8,601 | $7.44 | $64.0K | Form 4 |
| Nov 16, 2026 | Kathleen FordChief Operating Officer | 10b5-1 | 7,042 | $7.44 | $52.4K | Form 4 |
| Nov 16, 2026 | Troy Edward WilsonPresident and CEO | 101.1K | $7.42 | $750.3K | Form 4 | |
| Nov 13, 2026 | Troy Edward WilsonPresident and CEO | 98.9K | $7.63 | $754.5K | Form 4 | |
| Sep 29, 2026 | Kathleen FordChief Operating Officer | 10b5-1 | 3,668 | $10.75 | $39.4K | Form 4 |
| Sep 29, 2026 | Mollie LeoniChief Medical Officer | 10b5-1 | 28.8K | $10.75 | $309.6K | Form 4 |
| Sep 29, 2026 | Brian T. PowlChief Commercial Officer | 10b5-1 | 15.4K | $10.75 | $165.9K | Form 4 |
| Sep 28, 2026 | Teresa Brophy BairChief Legal Officer | 10b5-1 | 8,442 | $10.50 | $88.6K | Form 4 |
| Sep 28, 2026 | Kathleen FordChief Operating Officer | 10b5-1 | 6,906 | $10.50 | $72.5K | Form 4 |
| Sep 28, 2026 | Mollie LeoniChief Medical Officer | 12.4K | $10.50 | $130.7K | Form 4 | |
| Sep 28, 2026 | Thomas James DoyleSVP, Finance & Accounting | 4,607 | $10.50 | $48.4K | Form 4 | |
| Sep 28, 2026 | Brian T. PowlChief Commercial Officer | 9,020 | $10.50 | $94.7K | Form 4 | |
| Sep 28, 2026 | Brian T. PowlChief Commercial Officer | 10b5-1 | 8,000 | $10.56 | $84.5K | Form 4 |
| Sep 24, 2026 | Francis BurrowsChief Scientific Officer | 30.0K | $6.15 | $184.5K | Form 4 | |
| Sep 24, 2026 | Francis BurrowsChief Scientific Officer | 20.7K | $10.83 | $224.5K | Form 4 | |
| Aug 24, 2026 | Troy Edward WilsonPresident and CEO | 100.0K | $12.39 | $1.2M | Form 4 | |
| Aug 21, 2026 | Brian T. PowlChief Commercial Officer | 10b5-1 | 4,345 | $11.89 | $51.7K | Form 4 |
| Aug 19, 2026 | Teresa Brophy BairChief Legal Officer | 10b5-1 | 31.5K | $12.63 | $397.7K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 4, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by KURA's officers and directors from 2015 up to November 21, 2025, 11 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 6 more, back to 2015
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Biotechnology Value Fund L Pwith 9 more personsShare of class9.99%
- Montanova Capital, LLCwith 2 more personsShare of class9.70%
- BlackRock, Inc.Share of class8.90%
- State StreetShare of class5.70%
- Vanguard Capital ManagementShare of class5.01%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Biotechnology Value Fund L Pwith 9 more persons | 9.99% | 8.68M | Nov 14, 20253 filings since Feb 4, 2025 | 13G/A | |
| Montanova Capital, LLCwith 2 more persons | 9.70% | 8.58M | Aug 14, 20263 filings since Feb 13, 2025 | 13G/A | |
| BlackRock, Inc. | 8.90% | 7.91M | Oct 27, 20263 filings since Jan 8, 2025 | 13G/A | |
| State Street | 5.70% | 4.93M | Feb 9, 2026 | 13G | |
| Vanguard Capital Management | 5.01% | 4.43M | Apr 30, 2026 | 13G |
Fell to 5% or less (6)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Renaissance TechnologiesIn the quarter+21%
- AQR CapitalIn the quarter+18%
- Citadel Advisors (Griffin)In the quarter+107%
- Millennium Mgmt (Englander)In the quarter-50%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Renaissance Technologies | 2.01M | +21% | $22M | 0.03% |
| AQR Capital | 3.69M | +18% | $40M | 0.01% |
| Citadel Advisors (Griffin) | 680.1K | +107% | $7.3M | 0.00% |
| Millennium Mgmt (Englander) | 358.4K | -50% | $3.8M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 16.2% of its shares outstanding were held short, -0.7% since the report before.
- Shares held short
- 14.32M
- 16.2%
- Since the report before14.42M on Sep 30, 2026
- -0.7%
- 8.6
- 1.67M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 86%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 10.10M
- Nov 15, 2023: Shares held short 10.87M
- Nov 30, 2023: Shares held short 11.08M
- Dec 15, 2023: Shares held short 11.01M
- Dec 29, 2023: Shares held short 9.26M
- Jan 12, 2024: Shares held short 9.37M
- Jan 31, 2024: Shares held short 9.37M
- Feb 15, 2024: Shares held short 10.51M
- Feb 29, 2024: Shares held short 11.02M
- Mar 15, 2024: Shares held short 10.30M
- Mar 28, 2024: Shares held short 10.41M
- Apr 15, 2024: Shares held short 10.12M
- Apr 30, 2024: Shares held short 10.35M
- May 15, 2024: Shares held short 10.31M
- May 31, 2024: Shares held short 9.88M
- Jun 14, 2024: Shares held short 9.84M
- Jun 28, 2024: Shares held short 8.74M
- Jul 15, 2024: Shares held short 8.90M
- Jul 31, 2024: Shares held short 9.26M
- Aug 15, 2024: Shares held short 10.40M
- Aug 30, 2024: Shares held short 10.80M
- Sep 13, 2024: Shares held short 10.75M
- Sep 30, 2024: Shares held short 10.19M
- Oct 15, 2024: Shares held short 9.29M
- Oct 31, 2024: Shares held short 10.80M
- Nov 15, 2024: Shares held short 11.03M
- Nov 29, 2024: Shares held short 7.31M
- Dec 13, 2024: Shares held short 8.89M
- Dec 31, 2024: Shares held short 10.44M
- Jan 15, 2025: Shares held short 8.14M
- Jan 31, 2025: Shares held short 8.08M
- Feb 14, 2025: Shares held short 9.25M
- Feb 28, 2025: Shares held short 9.21M
- Mar 14, 2025: Shares held short 9.02M
- Mar 31, 2025: Shares held short 8.80M
- Apr 15, 2025: Shares held short 8.68M
- Apr 30, 2025: Shares held short 8.28M
- May 15, 2025: Shares held short 7.95M
- May 30, 2025: Shares held short 8.36M
- Jun 13, 2025: Shares held short 7.90M
- Jun 30, 2025: Shares held short 7.86M
- Jul 15, 2025: Shares held short 8.41M
- Jul 31, 2025: Shares held short 7.91M
- Aug 15, 2025: Shares held short 8.00M
- Aug 29, 2025: Shares held short 8.41M
- Sep 15, 2025: Shares held short 10.85M
- Sep 30, 2025: Shares held short 10.41M
- Oct 15, 2025: Shares held short 10.61M
- Oct 31, 2025: Shares held short 8.68M
- Nov 14, 2025: Shares held short 8.74M
- Nov 28, 2025: Shares held short 7.99M
- Dec 15, 2025: Shares held short 8.22M
- Dec 31, 2025: Shares held short 11.31M
- Jan 15, 2026: Shares held short 12.31M
- Jan 30, 2026: Shares held short 13.63M
- Feb 13, 2026: Shares held short 14.05M
- Feb 27, 2026: Shares held short 14.58M
- Mar 13, 2026: Shares held short 14.38M
- Mar 31, 2026: Shares held short 14.20M
- Apr 15, 2026: Shares held short 15.01M
- Apr 30, 2026: Shares held short 15.43M
- May 15, 2026: Shares held short 15.64M
- May 29, 2026: Shares held short 13.59M
- Jun 15, 2026: Shares held short 14.60M
- Jun 30, 2026: Shares held short 15.09M
- Jul 15, 2026: Shares held short 13.73M
- Jul 31, 2026: Shares held short 13.16M
- Aug 14, 2026: Shares held short 13.12M
- Aug 31, 2026: Shares held short 13.42M
- Sep 15, 2026: Shares held short 14.82M
- Sep 30, 2026: Shares held short 14.42M
- Oct 15, 2026: Shares held short 14.32M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading52.4% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 52.4% of the shares in the reported trades were short sales, against 64.0% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 52.4%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 64.0%
- Change
- -11.6 pts
- Short sales a dayon average, of 1.26M shares
- 659.2K
- More than atof 3,666 US-listed companies, same days
- 57%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 62.6%
- Oct 15, 2026: Short sales 64.1%
- Oct 16, 2026: Short sales 66.6%
- Oct 19, 2026: Short sales 63.4%
- Oct 20, 2026: Short sales 66.9%
- Oct 21, 2026: Short sales 60.9%
- Oct 22, 2026: Short sales 64.1%
- Oct 23, 2026: Short sales 79.3%
- Oct 26, 2026: Short sales 55.3%
- Oct 27, 2026: Short sales 49.6%
- Oct 28, 2026: Short sales 57.7%
- Oct 29, 2026: Short sales 51.9%
- Oct 30, 2026: Short sales 74.1%
- Nov 2, 2026: Short sales 73.3%
- Nov 3, 2026: Short sales 71.1%
- Nov 4, 2026: Short sales 46.6%
- Nov 5, 2026: Short sales 53.5%
- Nov 6, 2026: Short sales 45.6%
- Nov 9, 2026: Short sales 50.6%
- Nov 10, 2026: Short sales 48.4%
- Nov 11, 2026: Short sales 62.2%
- Nov 12, 2026: Short sales 62.5%
- Nov 13, 2026: Short sales 53.6%
- Nov 16, 2026: Short sales 44.9%
- Nov 17, 2026: Short sales 53.1%
- Nov 18, 2026: Short sales 55.5%
- Nov 19, 2026: Short sales 53.8%
- Nov 20, 2026: Short sales 48.5%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Troy Edward WilsonPresident and CEODirectly935.5K
- Teresa Brophy BairChief Legal OfficerDirectly178.4K
- Thomas James DoyleSVP, Finance & AccountingDirectly138.6K
- Kathleen FordChief Operating OfficerDirectly132.3K
- Brian T. PowlChief Commercial OfficerDirectly112.8K
- Mollie LeoniChief Medical OfficerDirectly99.8K
- Francis BurrowsChief Scientific OfficerDirectly42.3K
- Stephen DaleChief Medical OfficerDirectly38.8K
- Faheem HasnainDirectorDirectly24.0K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Troy Edward WilsonPresident and CEO | 935.5K | 479.2K | Nov 16, 2026 | Form 4 |
| Teresa Brophy BairChief Legal Officer | 178.4K | – | Nov 16, 2026 | Form 4 |
| Thomas James DoyleSVP, Finance & Accounting | 138.6K | – | Nov 16, 2026 | Form 4 |
| Kathleen FordChief Operating Officer | 132.3K | – | Nov 17, 2026 | Form 4 |
| Brian T. PowlChief Commercial Officer | 112.8K | – | Nov 19, 2026 | Form 4 |
| Mollie LeoniChief Medical Officer | 99.8K | – | Nov 17, 2026 | Form 4 |
| Francis BurrowsChief Scientific Officer | 42.3K | – | Sep 24, 2026 | Form 4 |
| Stephen DaleChief Medical Officer | 38.8K | – | Jan 30, 2024 | Form 4 |
| Faheem HasnainDirector | 24.0K | – | Dec 9, 2025 | Form 4 |
A lower bound: it counts only the 9 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.32%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.19%
- IBBiShares Biotechnology ETFWeight in the fund0.07%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.06%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.05%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.03%
- IWMiShares Russell 2000 ETFWeight in the fund0.03%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.02%
- VHTVanguard Health Care Index FundWeight in the fund0.01%
- VXFVanguard Extended Market Index FundWeight in the fund0.01%
18 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 201
- Q4 2025: Managers 217
- Q1 2026: Managers 224
- Q2 2026: Managers 220
Institutional investors by quarter
The fund managers holding KURA, quarter by quarter, from Q4 2015 to Q2 2025, 39 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 220 managers held 87.21M shares, worth $956M. During the quarter 28 opened a position, 32 closed one, 89 added and 63 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+9.0%
- Montanova CapitalIn the quarter
- BvfIn the quarter
- State StreetIn the quarter+18%
- Vanguard Capital ManagementIn the quarter+3.4%
- Armistice CapitalIn the quarter-1.6%
- AQR CapitalIn the quarter+47%
- Goldman Sachs GroupIn the quarter+58%
- Geode Capital ManagementIn the quarter+9.6%
- Alethea Capital ManagementIn the quarter+42%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 10.51M | +9.0% | $115M |
| Montanova Capital | 8.58M | $94M | |
| Bvf | 8.45M | $93M | |
| State Street | 5.33M | +18% | $58M |
| Vanguard Capital Management | 3.92M | +3.4% | $43M |
| Armistice Capital | 3.68M | -1.6% | $40M |
| AQR Capital | 3.13M | +47% | $34M |
| Goldman Sachs Group | 2.27M | +58% | $25M |
| Geode Capital Management | 2.23M | +9.6% | $24M |
| Alethea Capital Management | 2.17M | +42% | $24M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Kura Oncology's filings show?
Who buys and sells is one part of Kura Oncology's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have KURA's insiders bought or sold?
From Jun 4, 2026 to Nov 19, 2026 Kura Oncology's insiders bought $3.9M and sold $3.2M of shares on the market. 77% of the sales were under set 10b5-1 plans.
Which well-known managers hold KURA?
4 of the managers we track held the shares on Sep 30, 2026. The largest position was AQR Capital's, worth $40M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.